Creative Planning’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.32M | Buy |
134,203
+64,276
| +92% | +$1.53M | ﹤0.01% | 1494 |
|
|
2025
Q4 | $1.63M | Buy |
69,927
+49,642
| +245% | +$1.11M | ﹤0.01% | 1885 |
|
|
2025
Q3 | $400K | Buy |
20,285
+3,900
| +24% | +$80.2K | ﹤0.01% | 2925 |
|
|
2025
Q2 | $356K | Buy |
16,385
+2,689
| +20% | +$63.5K | ﹤0.01% | 2753 |
|
|
2025
Q1 | $332K | Buy |
13,696
+592
| +5% | +$13.3K | ﹤0.01% | 2658 |
|
|
2024
Q4 | $273K | Buy |
13,104
+380
| +3% | +$8.16K | ﹤0.01% | 2736 |
|
|
2024
Q3 | $253K | Buy |
12,724
+2,699
| +27% | +$50K | ﹤0.01% | 2664 |
|
|
2024
Q2 | $155K | Buy |
+10,025
| New | +$156K | ﹤0.01% | 2745 |
|
|
2020
Q3 | – | Sell |
-34,608
| Closed | -$160K | – | 2171 |
|
|
2020
Q2 | $160K | Buy |
+34,608
| New | +$156K | ﹤0.01% | 1580 |
|
|
2020
Q1 | – | Sell |
-22,725
| Closed | -$85K | – | 1906 |
|
|
2019
Q4 | $85K | Buy |
22,725
+6,975
| +44% | +$32.6K | ﹤0.01% | 1770 |
|
|
2019
Q3 | $84K | Buy |
+15,750
| New | +$83.9K | ﹤0.01% | 1739 |
|
|
2017
Q4 | – | Sell |
-10,681
| Closed | -$27K | – | 1922 |
|
|
2017
Q3 | $27K | Hold |
10,681
| – | – | ﹤0.01% | 1821 |
|
|
2017
Q2 | $29K | Hold |
10,681
| – | – | ﹤0.01% | 2904 |
|
|
2017
Q1 | $21K | Sell |
10,681
-6,000
| -36% | -$7.64K | ﹤0.01% | 3089 |
|
|
2016
Q4 | $18K | Buy |
16,681
+6,000
| +56% | +$6.85K | ﹤0.01% | 3135 |
|
|
2016
Q3 | $12K | Sell |
10,681
-4,100
| -28% | -$3.69K | ﹤0.01% | 3380 |
|
|
2016
Q2 | $10K | Buy |
14,781
+950
| +7% | +$765 | ﹤0.01% | 3239 |
|
|
2016
Q1 | $16K | Sell |
13,831
-7,350
| -35% | -$11.4K | ﹤0.01% | 2904 |
|
|
2015
Q4 | $52K | Buy |
21,181
+12,400
| +141% | +$35.5K | ﹤0.01% | 2083 |
|
|
2015
Q3 | $26K | Buy |
+8,781
| New | +$37.9K | ﹤0.01% | 2513 |
|
|
2015
Q2 | – | Sell |
-8,231
| Closed | -$36K | – | 1465 |
|
|
2015
Q1 | $36K | Sell |
8,231
-1,120
| -12% | -$4.04K | ﹤0.01% | 2247 |
|
|
2014
Q4 | $28K | Buy |
9,351
+1,120
| +14% | +$3.07K | ﹤0.01% | 2392 |
|
|
2014
Q3 | $27K | Hold |
8,231
| – | – | ﹤0.01% | 2316 |
|
|
2014
Q2 | $21K | Hold |
8,231
| – | – | ﹤0.01% | 2448 |
|
|
2014
Q1 | $19K | Buy |
8,231
+50
| +0.6% | +$105 | ﹤0.01% | 2403 |
|
|
2013
Q4 | $16K | Hold |
8,181
| – | – | ﹤0.01% | 2308 |
|
|
2013
Q3 | $25K | Sell |
8,181
-1,274
| -13% | -$2.14K | ﹤0.01% | 1959 |
|
|
2013
Q2 | $8K | Buy |
+9,455
| New | +$7.57K | ﹤0.01% | 2349 |
|
Other funds holding CPRX
VCM
DM
VPM
Creative Planning's CPRX Position: Q1 2026 in Review
Creative Planning increased its Catalyst Pharmaceutical (CPRX) stake by 92% in Q1 2026, buying an estimated $1.53M and bringing the position to 134,203 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1494.
Creative Planning first reported a position in CPRX in Q2 2013 and has held it in 28 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Creative Planning held 134,203 shares of Catalyst Pharmaceutical worth $3.32M as of Q1 2026.
- Creative Planning bought 64,276 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.53M.
- Catalyst Pharmaceutical made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1494 holding.
- Creative Planning first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 28 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.